Having led multinational pharmaceutical companies, we asked ourselves in 2012, how would our careers be defined and what contributions could we now be making. Most individuals reach a stage, where having a bigger purpose in life by which to define one’s legacy, becomes the main motivation. Something to be proud of sharing with your children. That reflection led to the birth of Genpharm.
Looking at the rare disease environment in the Middle East region and the significant gaps in meeting patients’ needs, we decided to take on these challenges.
Rare and genetic diseases are prevalent in the region due to the higher rate of consanguine marriages and rather large family size. Nevertheless, the small number of experts, the lack of disease awareness and timely diagnosis makes the patient pathway littered with obstacles. These diseases are generally pediatric in nature and have a significant socio-economic impact on families and society. They have a major influence on quality of life and life-expectancy.
On the bright side, the advances in scientific research, the number of on-going clinical trials in rare diseases and pushing the boundaries of cell and gene therapy have started showing breakthroughs in treating some of these diseases.
We want to be at the core of this trend in the MENA region and facilitate access to these innovative therapies. Hence, everything we do at Genpharm is focused on helping the patients and their families.
From our mantra: “Bringing Cures to MENA Patients”;
To our tag line “Commit. Connect. Cure”;
To our three core values:
“We Always Put Patients First”;
“We are Passionate about what we do”;
“We Deliver on Our Promises”;
Patients are at the core of our purpose.
Karim Smaira Kamel Ghammachi